{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Cancer Institute (NCI) and the Clinical Center (CC), National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive license to Advanced Imaging Projects, LLC, a company having a place of business in Boca Raton, FL, to practice the inventions embodied in the following patent applications:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/09/02/2016-21113.html","cfr_references":[],"citation":"81 FR 60710","comment_url":null,"comments_close_on":"2016-09-19","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before September 19, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-21113","effective_on":null,"end_page":60710,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/09/02/2016-21113.xml","html_url":"https://www.federalregister.gov/documents/2016/09/02/2016-21113/prospective-grant-of-exclusive-patent-license-development-of-integrin-v3-antagonists-for-use-in","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-21113?publication_date=2016-09-02","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-09-02/2016-21113/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":194,"last_updated":"2026-08-25 00:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-09-02/pdf/2016-21113.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-21113.pdf?1472733934","publication_date":"2016-09-02","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/09/02/2016-21113.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T21:02:05Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":60710,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development of Integrin αvβ3 Antagonists for Use in Imaging and Therapy","toc_doc":"Development of Integrin a-v beta-3 Antagonists for use in Imaging and Therapy","toc_subject":"Prospective Grant of Exclusive Patent License:","topics":[],"type":"Notice","volume":81}